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Abstract: Present review describes research on novel natural cyclobutane-containing alkaloids isolated from terrestrial 
and marine species. More than 60 biological active compounds have been confirmed to have antimicrobial, antibacterial, 
antitumor, and other activities. The structures, synthesis, origins, and biological activities of a selection of cyclobutane-
containing alkaloids are reviewed. With the computer program PASS some additional biological activities are also pre-
dicted, which point toward new possible applications of these compounds. This review emphasizes the role of cyclobu-
tane-containing alkaloids as an important source of leads for drug discovery. 
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INTRODUCTION 
  Organic compounds containing four-membered ring(s) 
represent unusual group of metabolites including natural 
products and/or drugs. The cyclobutane unit is found as a 
basic structural element in a wide range of naturally occur-
ring compounds in bacteria, fungi, plants, and marine inver-
tebrates. It is also generated transiently in primary and sec-
ondary metabolisms [1]. Many biological activities are 
showed and may serve as potential drug leads or provide 
new ideas for the study of enzyme mechanisms, and/or or-
ganic synthesis [2]. Some cyclobutane compounds such as 
amino acids, peptides and nucleosides showed protective 
properties against UV radiation [3]. In the skin many mole-
cules may absorb UV radiation upon exposure. In particular, 
cellular DNA strongly absorbs shorter wavelength solar UV 
radiation, resulting in various types of DNA damage. Among 
the DNA photoproducts produced the cyclobutane 
pyrimidine dimers are predominant [4]. 
  Although cyclobutanes have been known for more than a 
century, their use as synthetic intermediates has only flour-
ished in the last forty years. The structures and syntheses of 
cyclobutanoid fatty acids, amino acids, mono-, sesqui-, di-, 
and triterpenes, steroids, and other compounds have recently 
been reported [2,5,6]. 
  In the present review, we will focus on origin, structures, 
and biological activities of natural cyclobutane-containing 
alkaloids and selected related compounds. Their structure 
and biological activities, modes of action, and future pros-
pects are discussed. 
  This paper is a short survey of cyclobutane-containing 
alkaloids that are deemed as naturally occurring. Also, this is  
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the first article to review natural alkaloids comprising a cy-
clobutane unit. 
TERRESTRIAL CYCLOBUTANE-CONTAINING AL-
KALOIDS 
  GC-MS was used to analyze volatiles in the headspace of 
'Fortress' onion bulbs inoculated with Fusarium oxysporum, 
Botrytis allii, Erwinia carotovora subsp. carotovora, Asper-
gillus niger, or Penicillium aurantiogriseum. Among 130 
volatile metabolites of 'Fortress' onion bulbs were found a 
simple ethylcyclobutane and 2-azabicyclo[3.2.0]hept-6-ene 
(1) [7]. 2,4-Methanoproline (2-carboxy-2,4-methanopyrroli-
dine) (2) and 2,4-methanoglutamic acid (1-amino-1,3-
dicarboxycyclobutane) were isolated from seeds of Ateleia 
herbert smithii (Leguminosae) [8]. 
  The non-protein amino acids of the legume genus Bocoa 
(Papilionoideae; Swartzieae) were surveyed by LC-MS and 
GC-MS using extracts of herbarium leaf fragments. 2,4-
Methanoproline (2) have also been detected in Ateleia her-
bert smithii, Bocoa alterna, B. decipiens, B. limae, B. mollis, 
and  B. racemulosa [9]. Compound (2) was formerly sug-
gested to have insect repellent/antifeedant activity [10]. 
  Synthesis of 2,4-methanoproline and derivatives have 
been reported by several authors. Most of the syntheses of 
2,4-methanoproline are accomplished by an intramolecular 
light-induced [2+2] cycloaddition of an appropriate diene 
[11,12]. Only Gaoni used an intramolecular cyclization strat-
egy for his approach [13]. Also analogues containing the 2-
azabicyclo[2.1.1]hexane skeleton are often synthesized by 
the light-induced [2+2] cyclization [14-17]. The rearrange-
ment of an appropriate bromohydrine to synthesize 5-
hydroxy-2-azabicyclo[2.1.1]-hexanes has also been de-
scribed [18,19]. A two-step synthetic approach toward 3-
(chloromethyl)cyclobutanone was described and used in the 
synthesis of 2,4-methanoproline analogues [20]. The key Cyclobutane-Containing Alkaloids  The Open Medicinal Chemistry Journal, 2008, Volume 2    27 
step consists of a reversible addition of hydrogen cyanide 
onto the imines (Scheme 1). 
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Scheme 1. 
  Seven Lycopodium alkaloids, lannotinidines A-G, have 
been isolated from the club moss Lycopodium annotinum 
and L. annotinum var. acrifolium. Two lannotinidines F (3) 
and E (4) contain cyclobutane ring elevated NGF mRNA 
expression. Effects of lannotinidines A–F on neurotrophic 
factor biosynthesis in 1321N1 human astrocytoma cells were 
examined by determining NGF mRNA expression. 1321N1 
cells were incubated with 30 μg/mL each of lannotinidines 
A–F for 6 h, and the mRNA expressions of NGF in 1321N1 
cells were examined by a semiquantitative RT-PCR method. 
The mRNA expressions for NGF were enhanced by lannoti-
nidines B–E, among which (3) was the most potent [21]. 
 Bioactive  hexahydro-1',10'-dimethyl-spiro[cyclo-butane-
1,8'(7'H)-[1H-5,8a]propane-quinolin]-7'-one (5) was isolated 
from extract of Lycopodium species [22]. Unusual tetrame-
thyl-N,N-bis(2,6-dimethyl-phenyl)-cyclobutane-1,3-diimine 
(6), triacontanol, and tricin, reported from Arundo donax, 
revieled significant antifeedant activity against the boll wee-
vil, Anthonomus grand [23]. 
 Sarcomelicope  megistophylla (Rutaceae) is a small to 
medium sized tree, 8–12 m high, easily recognized by its 
pubescent leaves, exceptionally large for the genus (up to 35 
cm long). This species is endemic to the region of Néaoua, 
New Caledonia [24]. A new quinolone, cyclomegistine (7), 
was isolated from the bark of Sarcomelicope megistophylla. 
This alkaloid possesses the cyclobuta[b]quinoline ring sys-
tem that has not been previously described either from natu-
ral or from synthetic origin. Biogenetically, cyclomegistine 
could arise from the oxidative aromatic ring cleavage of an 
acridone precursor, followed by photo-isomerization of the 
resulting butadiene into the isomeric cyclobutane [25]. 
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  A tropane alkaloid with a 2-methyl-4-phenyl-cyclobutane 
1,2,3-tricarboxylic acid ester as the central structure was 
isolated from the aerial parts of Schizanthus grahamii and 
named grahamine (8) [26]. 
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  Two new dimeric tropane alkaloids, mooniines A (9) and 
B (10) were identified from the leaves of Erythroxylum 
moonii [27]. 
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 Adenocarpus  complicatus subspecies aureus (Papiliona-
cea) yielded alkaloids: (+)-santiaguine (0.14%, 11), racemic 
santiaguine (0.01%), (+)-adenocarpine (0.23%), and   
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isoorensin (0.18% of dried plant) [28]. Santiaguine has also 
been isolated from Adenocarpus mannii, Adenocarpus folio-
sus, Adenocarpus intermedius and A. parvifolius [29-40]. 
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  Structures of monoterpene alkaloid derivatives and sper-
mine related compounds (12,13) isolated from Incarvillea 
sinensis were detected by physico-chemical methods. 
Among them, incarvilateine (13) showed strongest analgesic 
and sedative activities [41,42]. Methoxyincarvillateine (14), 
and the N-oxides (15) with similarly structure  have been 
obtained from extract of the Incarvillea sinensis [43]. 
  The [2+2] photodimerization of trans-cinnamic acids in 
the crystalline state gave R-truxillic acid. Condensation of 
the R-truxillic acid with 2 equiv of the above-described (+)-
6-epi-incarvilline under Mitsunobu conditions produced to-
syl-protected incarvillateine (Scheme 2). Deprotection of the 
tosyl groups using sodium amalgam in methanol provided (-
)-incarvillateine (13) as colorless crystals. The optical rota-
tion and spectroscopic properties (
1H and 
13C NMR) of syn-
thetic (13) were in agreement with those reported for natural 
incarvillateine [44]. 
  A re-examination of the leaf and seed alkaloids of Lu-
pinus cosentinii, confirmed in both parts the presence of epi-
lupinine, epilupinine N-oxide, and multiflorine. Both organs 
of the plant contained a new tricyclic alkaloid (16) [45]. 
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 Thesine  (17), isolated from Thesium minkwizianum and 
its water-soluble sulfate, showed extremely toxic properties; 
the initial oral dosage should be about 10-20 mg [46-48]. 
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Scheme 2. 
 The  genus  Piper (Piperaceae) includes more than 1000 
species making it one of the largest genera of basal angio-
sperms [49]. Piper species are distributed pantropically and 
are in the form of shrubs, herbs, and lianas common in the 
understory of lowland wet forests. The greatest diversity of Cyclobutane-Containing Alkaloids  The Open Medicinal Chemistry Journal, 2008, Volume 2    29 
Piper species occurs in the American tropics (700 spp.), fol-
lowed by Southern Asia (300 spp.), where the economically 
important species Piper nigrum (Black pepper) and P. betle  
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(betel leaf) originated. Patterns of distribution of Piper spe-
cies vary from being locally endemic to widespread. Several 
cyclobutane-containing alkaloids have been isolated and 
identified from the genus Piper [50]. Fifteen novel dimeric 
amide alkaloids possessing a cyclohexene ring, nigramides 
A-O, as well as four novel dimeric amide alkaloids possess-
ing a cyclobutane ring, nigramides P-S (18-21), have been 
isolated from the roots of Piper nigrum. The biosynthetic 
hypothesis of nigramides A-O was proposed by an intermo-
lecular Diels-Alder reaction from the corresponding mono-
meric amides [51]. 
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  Two other new alkaloids possessing a cyclobutane ring, 
named pipercyclobutanamides A (22) and B (23), have been 
isolated from the fruits of Piper nigrum [52]. Isolated com-
pounds were potent mechanism-based inhibitors of cyto-
chrome P 450 2D6 (CYP2D6) [53,54]. 
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  Two new cyclobutanoid amides, piplartine-dimer A (24), 
piperarborenine A (25) and B (26), and piperarboresine (27) 
were isolated from the stem of Piper arborescens [55]. 
Piplartine dimer A (24) has also been obtained from extracts 
of three piper species: P. Aborescens, P. rugosum, P. tuber-
culatum [56-58]. 
  Three new cyclobutanoid amides with trans-trans con-
figurations, piperarborenine C (28), piperarborenine D (29) 30    The Open Medicinal Chemistry Journal, 2008, Volume 2  Sergeiko et al. 
and piperarborenine E (30), and a new furanoid lignan, (+)-
arborone, together with twelve known compounds, were 
isolated from the stems of Piper arborescens. Piperar-
borenine C, (+)-diayangambin, piplartine, piperolactam B, 
piperolactam C, aristolactam BIII, goniothalactam, and 
methyl  trans-3,4,5-trimethoxycinnamate possessed anti-
platelet aggregation activity in vitro. Among them, piplartine 
showed the most potent anti-platelet aggregation activity 
induced by collagen and showed an IC50 value of 21.5 μM. 
Piperarborenines C-E, piperarborenine, aristololactam BIII 
and goniothalactam showed significant cytotoxic activity 
(IC50 values < 4 μg/mL) against P-388, HT-29 and A549 cell 
lines in vitro [59]. 
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  Two new pyrrolidinamide dimers have been isolated 
from the leaves and stem of Piper peepuloides and their 
structures established by spectral analysis as cyclobutane-2-
(1,3-benzodioxol-5-methoxy-6-yl)-4-(1,3-benzodioxol-4,5-
dimethoxy-6-yl)-1,3-dicarboxa-pyrrolidide (31) and cyclobu-
tane-2,4-bis-(1,3-benzodioxol-5-methoxy-6-yl)-1,3-
dicarboxa-pyrrolidide (32) [60]. 
  Tremorgenic mycotoxins produced by fungi belonging to 
the genera Penicillium, Aspergillus, and Claviceps have po-
tent insecticidal and growth inhibitory activity against the 
corn earworm (Heliothis zea) and the fall armyworm 
(Spodoptera frugiperda) [61-65]. Several similar indole-
diterpenoid compounds with cyclobutyl unit have been iso-
lated from these fungi species. Mycotoxins produced by   
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several Penicillium species: P. crustosum, P. brevicompac-
tum, P. chrysogenum, P. expansum, P. roqueforti, P. spinu-
losum, P. viridicatum, P. commune, P. citrinum and P. soli-
tum, included mycophenolic acid, roquefortine C, penitrems 
A-F (33-38) and thomitrems A and E (41 and 42) [66-74]. 
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  Penitrem G (39), a new alkaloid, has been isolated to-
gether with the already known mycotoxins penitrems A-D 
and F from the mycelium of Penicillium crustosum [75]. 
Penitrems A-D and F showed convulsive and insecticidal 
activities against both insect species. A prominent novel ana-
log pennigritrem (40) of penitrem A, resolved from the 
tremorgenic alkaloids of a strain of Penicillium nigricans, 
showed to involve the terminal diterpenoid isoprene in a 
cyclization which is unique among fungal indole-
diterpenoids [76]. 
  Recently the minor metabolites, PC-M5' and PC-M6, 
were isolated along with the tremorgenic mycotoxins, peni-
trems A-F, from the mycelium of P. crusotsum, were found 
as contaminats of bread intended for school lunches in To-
kyo city. Two new indoloditerpenes, PC-M4 (43) and PC-
M5, were also isolated from the above fungus. PC-M4 has 
the same carbon number as the penitrems but a different cy-
clic ring system. PC-M5 might be a biosynthetic precursor of 
penitrems and PC-M4 as may also be PC-M5' and PC-M6 
[77]. 
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 The new antiinsectan metabolite 10-oxo-11,33-
dihydropenitrem B (44) was isolated from the sclerotia of 
Aspergillus sulphureus. Isolated alkaloid is related to the 
penitrems, a known group of tremorgenic fungal metabolites. 
A known aflavinine analog (10,23-dihydro-24,25-
dehydroaflavinine) was also isolated from A. sulphurerus 
sclerotia. This is the first report of any aflavinine analog 
from a member of the Aspergillus ochraceus taxonomic 
group [78]. 
  Extract from the sclerotia of Aspergillus sulphureus 
yielded four new antiinsectan compounds of the 
paspaline/penitrem class, and included secopenitrem B (45). 
Isolated metabolites were structurally related to penitrems. 
The three indole metabolites, including (45), exhibited po-
tent activity against the lepidopteran crop pest Helicoverpa 
zea [79]. 
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  A new group of microbial metabolites, designated peni-
tremones A-C, have been characterized by MS and NMR 
spectroscopy as 10-keto, and 11,33-dihydro-variants of the 
penitrem indole-isoprenoid skeleton. The principal metabo-
lite penitremone A (46), and minor (47) produced with peni-
trem A by a Penicillium sp., is an isomer of penitrem E and 
was also similarly tremorgenic [80]. Different biological 
activities for penitrem A (33) have been studied and reported 
in some articles [81-88]. 
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  Recently, Smith III and co-workers [89] demonstrated 
the viability of a highly stereoselective tandem Mannich cy-
clization-grammine fragmentation/addition cascade, critical 
for assembly of the A and F rings of penitrem D (Scheme 3). 
They also explored simultaneous execution of this tactic with 
concurrent construction of ring I. Reinvestigation of a model 
system provided an explanation for the unanticipated stereo-
chemical outcome at C(28). 
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Scheme 3. 
PREDICTED ACTIVITIES OF ALKALOIDS ISO-
LATED FROM TERRESTRIAL SPECIES 
  Probable additional biological activities of cyclobutane-
containing alkaloids were evaluated by computer prediction. 
For this purpose we used computer program ‘PASS’ [90-92], 
which predicts about 2,500 pharmacological effects, mecha-
nisms of action, mutagenicity, carcinogenicity, teratogenicity 
and embryotoxicity on the basis of structural formulae of 
compounds. PASS predictions are based on structure-activity 
relationships (SAR) analysis of the training set consisting of 
about 60,000 drugs, drug-candidates and lead compounds. 
Algorithm of PASS predictions is described in detail in sev-
eral publications [91,92]. Using MOL or SD files as an input 
for the PASS program, user may get a list of probable bio-
logical activities for any drug-like molecule as was also pub-
lished recently [90]. 
  For each activity, Pa and Pi values are calculated, which 
can be interpreted either as the probabilities of a molecule 
belonging to the classes of active and inactive compounds,  
 
Table 1.  Predicted Biological Activities for Compounds Iso-
lated from Terrestrial Sources 
 
No.  Drug-Likeness  Focal Activity Prediction 
1  0.971  Pa = 0.964 Pi = 0.003 
Aryl-acylamidase inhibitor 
2  0.991  Pa = 0.895 Pi = 0.006 
Dopamine release stimulant 
3  0.965  Pa = 0.938 Pi = 0.005 
Phosphatase inhibitor 
4  0.992  Pa = 0.939 Pi = 0.005 
Phosphatase inhibitor 
5  0.958  Pa = 0.840 Pi = 0.008 
Membrane integrity antagonist 
6  0.055  Pa = 0.931 Pi = 0.001 
D-amino-acid dehydrogenase inhibitor 
7  0.832  Pa = 0.824 Pi = 0.007 
Amyotrophic lateral sclerosis treatment 
8  0.992  Pa = 0.728 Pi = 0.015 
Dependence treatment 
9  0.983  Pa = 0.769 Pi = 0.011 
Dependence treatment 
10  0.972  Pa = 0.820 Pi = 0.007 
Dependence treatment 
11  0.913  Pa = 0.775 Pi = 0.022 
Neuroprotector 
12  0.966  Pa = 0.855 Pi = 0.008 
Pulmonary hypertension treatment 
13  0.967  Pa = 0.848 Pi = 0.008 
Pulmonary hypertension treatment 
14  0.968  Pa = 0.841 Pi = 0.009 
Pulmonary hypertension treatment 
15  0.984  Pa = 0.794 Pi = 0.015 
Pulmonary hypertension treatment 
16  0.964  Pa = 0.838 Pi = 0.010 
Dopamine release stimulant 
17  0.967  Pa = 0.808 Pi = 0.015 
Dopamine release stimulant 
18  0.903   Pa = 0.937 Pi = 0.002 
Cytochrome P450 inhibitor 
19  0.889  Pa = 0.974 Pi = 0.001 
Cytochrome P450 inhibitor 
20  0.903   Pa = 0.940 Pi = 0.002 
Cytochrome P450 inhibitor 
21  0.931  Pa = 0.960 Pi = 0.002 
Cytochrome P450 inhibitor 
22  0.954  Pa = 0.915 Pi = 0.003 
Cytochrome P450 inhibitor 
23  0.956  Pa = 0.966 Pi = 0.002 
Cytochrome P450 inhibitor 
24  0.907  Pa = 0.919 Pi = 0.018 
(-)-(4S)-limonene synthase inhibitor 
25  0.882  Pa = 0.941 Pi = 0.020 
(-)-(4S)-limonene synthase inhibitor 
26  0.896  Pa = 0.908 Pi = 0.022 
(-)-(4S)-limonene synthase inhibitor 
27  0.961  Pa = 0.853 Pi = 0.008 
Pulmonary hypertension treatment 
28  0.961  Pa = 0.853 Pi = 0.008 
Pulmonary hypertension treatment 
29  0.896  Pa = 0.908 Pi = 0.022 
(-)-(4S)-limonene synthase inhibitor 
30  0.950  Pa = 0.866 Pi = 0.038 
(-)-(4S)-limonene synthase inhibitor 
31  0.875  Pa = 0.915 Pi = 0.008 
Neuroprotector 
32  0.935  Pa = 0.933 Pi = 0.007 
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respectively, or as the probabilities of the first and second 
kind of errors in prediction. First kind error of prediction 
reflects the “false-positives”, when an inactive compound is 
predicted to be active; and second kind error of prediction: 
reflects the “false-negatives”, when an active compound is 
predicted to be inactive. 
  Interpretation of the predicted results and selection of the 
most prospective compounds are based on flexible criteria, 
which depend on the purpose of particular investigation. If 
the user chooses a rather high value of Pa as a threshold for 
selection of probable activities, the chance to confirm the 
predicted activities by the experiment is high too, but many 
existing activities will be lost. Typically, there are several 
dozen biological activities in the predicted biological activity 
spectra; activity that is predicted with the highest probability 
is called “focal”. Focal biological activities for cyclobutane-
containing alkaloids isolated from terrestrial sources are 
shown below in the Table 1. Additional predicted biological 
activities for cyclobutane-containing tremorgenic mycotox-
ins are shown in Table 2. 
Table 2.  Predicted Biological Activities for Tremorgenic My-
cotoxins 
 
No.  Drug-Likeness  Focal Activity Prediction 
33  0.991  Pa = 0.736 Pi = 0.015 
GABA A receptor antagonist 
34  0.993  Pa = 0.740 Pi = 0.014 
GABA A receptor antagonist 
35  0.992  Pa = 0.751 Pi = 0.012 
GABA A receptor antagonist 
36  0.992  Pa = 0.724 Pi = 0.017 
GABA A receptor antagonist 
37  0.993  Pa = 0.772 Pi = 0.056 
Phosphatase inhibitor 
38  0.994  Pa = 0.765 Pi = 0.059 
Phosphatase inhibitor 
39  0.994  Pa = 0.760 Pi = 0.061 
Phosphatase inhibitor 
40  0.988  Pa = 0.810 Pi = 0.038 
Phosphatase inhibitor 
41  0.992  Pa = 0.761 Pi = 0.061 
Phosphatase inhibitor 
42  0.993  Pa = 0.734 Pi = 0.015 
GABA A receptor antagonist 
43  0.993  Pa = 0.716 Pi = 0.025 
Ecdysone 20-monooxygenase inhibitor 
44  0.991  Pa = 0.739 Pi = 0.014 
GABA A receptor antagonist 
45  0.993  Pa = 0.742 Pi = 0.014 
GABA A receptor antagonist 
46  0.993  Pa = 0.722 Pi = 0.018 
GABA A receptor antagonist 
47  0.993  Pa = 0.735 Pi = 0.073 
Phosphatase inhibitor 
 
CYCLOBUTANE-CONTAINING ALKALOIDS FROM 
MARINE SPECIES 
  Cyclobutane-containing alkaloids have also been isolated 
and their structures elucidated from marine algae and inver-
tebrates, mainly from marine sponges. Some of them showed 
different biological activities. The water-soluble cyclobuta-
dithymine (48) was extracted from the marine red alga Por-
phyra yezoensis, and showed the protective properties 
against UV-A irradiation [93]. 
  John Faulkner from the University of California (Ber-
keley) was the first scientist who discovered an antimicrobial 
agent, sceptrin (49), from the sponge, Agelas sceptrum, at 
1981. This alkaloid exhibited antimicrobial activity against 
Staphylococcus aureus, Bacillus subtilis, Candida albicans, 
Pseudomonas aeruginosa,  Alternaria (fungus), and Cla-
dosporium cucumerinum. The compound (49) was not toxic 
at 50 mg/kg [94,95]. The influence of environmental factor, 
namely depth and sponge-coral interactions as well as the 
effects of infliction of standardized damages on the produc-
tion of bromopyrrolic alkaloids isolated from the sponges 
Agelas dispar and Agelas conifera were analyzed and scep-
trin (49) was detected in both sponge species [96]. More 
recently, sceptrin and eight dimeric bromopyrrole alkaloids, 
nagelamides A-H, and a monomeric one, 9,10-
dihydrokeramadine, have been isolated from the Okinawan 
marine sponge Agelas sp. Nagelamides A-H exhibited anti-
bacterial activity against Gram-positive bacteria. Nagelamide 
G inhibited protein phosphatase 2A activity [97]. Sceptrin, 
ageliferine and xestospongine B, three alkaloids isolated 
from  Xestospongia sp. and Agelas novaecaledoniae were 
reported as somatostatin and VIP inhibitors. Sceptrin and 
ageliferine showed an affinity for VIP (19.8 μM and 19.2 
μM, respectively). Due to the interaction between non-
peptidic compounds and somatostatin/VIP receptors, these 
three alkaloids could be promising agents in the research on 
natural non-peptidic compounds for therapeutical interven-
tions [98]. 
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  The mechanism of action of sceptrin was investigated 
[99]. Sceptrin has been reported to exhibit antibacterial and 34    The Open Medicinal Chemistry Journal, 2008, Volume 2  Sergeiko et al. 
antifungal activities. Sceptrin demonstrated a bacteriostatic 
rather than bactericidal effect at the MIC on exponentially 
growing Escherichia coli. Under these conditions, the cul-
ture produced chains of cells, and incorporation of radiola-
beled precursors into DNA, protein, and cell wall was unaf-
fected, whereas incorporation of 
3H-uridine into RNA was 
slightly inhibited. At concentrations higher than the MIC, 
sceptrin was bactericidal, inhibited the incorporation of all 
radiolabeled precursors, and induced the formation of un-
usual spheroplasts. Peptidoglycan turnover in E. coli ap-
peared to be stimulated by sceptrin, as demonstrated by a 
release of diaminopimelic acid-containing high mol wt mate-
rial. Subsequent studies of the release of K
+ from E. coli and 
the lysis of red blood cells suggested that sceptrin disrupts 
the cell membranes of both prokaryotic and eukaryotic cells. 
Spheroplast formation may reflect a cell wall effect that oc-
curs subsequent to membrane damage [99]. In a search for 
potential target sites for C11N5 compounds obtained from 
marine sponges of the genus Agelas, the authors evaluated 
their interaction with muscarinic acetylcholine receptors 
from rat brain membranes. In competition experiments with 
3H-QNB, these compounds displayed the following rank 
order of potency: sceptrin (49) > oroidin,  dibromosceptrin 
 clathrodin. Sceptrin (49) (50 μM) was shown to be a com-
petitive inhibitor of 3H-QNB binding as revealed Scatchard 
analysis. The results demonstrate the ability of these com-
pounds to interact with multiple molecule targets in the mi-
cromolar range [100]. 
  The first enantioselective total synthesis of sceptrin was 
reported by programming the fragmentation of an oxaquad-
ricyclane [101]. Oxabicycle (50) could be obtained in quanti-
tative yield by Alder reaction. In the [2+2] cyclization to 
form oxaquadricyclane (51), it was found that switching the 
solvent from diethyl ether to THF not only accelerated the 
reaction but also avoided potential complications due to the 
low boiling point of ether (Scheme 4). The highly unstable 
(51) was taken on in crude form to the fragmentation step.  
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Reagents and conditions: (a) DMAD (1.0 equiv), 2,5-dimethylfuran (1.2 
equiv), 1,4-dioxane, 100 °C, 12 h, quantitative; (b) 450 W Hanovia lamp, 
THF, 24 h, quantitative; (c) H2SO4, MeOH, 24 h, 50%; (d) MeOH, 
CH(OMe)3 (14 equiv), TsOH (0.15 equiv), 50°C, 24 h; DIBAL (6.0 equiv), 
CH2Cl2, -78 °C, 1.5 h, then AcOH, H2O, 10 min, quantitative; (e) MsCl 
(4.4 equiv), 20°C, 1 h; NaN3 (6.0 equiv), DMF, 50°C, 24 h, quantitative. 
DMAD = dimethyl acetylenedicarboxylate, THF = tetrahydrofuran, DIBAL 
= diisobutylaluminum hydride, DMF = N,N-dimethylformamide. 
Scheme 4. 
The known procedure for the fragmentation of oxaquadricy-
lane (51) gave only low yield of cyclobutane (52). As this 
was clearly not a viable option to support extensive synthetic 
efforts, a more expedient procedure was needed. It was 
found that the addition of diethyl ether after evaporation of 
methanol would cause the precipitation of cyclobutane (52) 
in ca. 50% yield, allowing expedient access to multigram 
quantities of (52). With the all-trans cyclobutane framework 
in place, (53) can be obtained. 
  Ketalization of (56) under standard conditions (Scheme 
5), followed by bromination of the crude ketal with phenyl-
trimethyl ammonium tribromide, gave bromoketone, dis-
placement of which gave with sodium diformamide com-
pound (54), which was hydrolyzed with aqueous HCl to give 
(55) and reacted with cyanamide to form (56) in 80% yield 
over three steps, thereby completing installation of the 2-
aminoimidazole, along with 5-10% of an oxazole byproduct 
[101]. 
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Reagents and conditions: (a) MeOH, CH(OMe)3 (14 equiv), TsOH (0.15 
equiv), 50°C, 24 h; PTT (2.1 equiv), THF/MeOH/CH(OMe)3 2:1:0.1, 20°C, 
2 h; AcOH(aq), 50°C, 12 h, 92%; (b) NaN(CHO)2 (6 equiv), MeCN, 18 h, 
20°C; (c) MeOH, HCl (1% v/v), 16 h; (d) H2NCN (80 equiv), H2O, 140°C 
μwave, 3 min, 80%. 
PTT = phenyltrimethylammonium tribromide, THF = tetrahydrofuran. 
Scheme 5. 
  Biologically active extracts of the Caribbean sponge 
Agelas conifera had yielded, in exhaustive studies, the diace-
tate salts of seven new bromopyrroles (57-61), as well as that 
of the known debromooroidin dimer sceptrin. These com-
pounds were found to be antiviral and antibacterial and were 
active in barnacle settlement and biochemical prophage in-
duction assays. The oxysceptrins are characterized by their 
aminoimidazolinone group, the ageliferins, by a unique cy-
clohexene-based skeleton [102]. Debromosceptrin (57), and 
two known pyrrole analogs (58 and 59) were also found in 
extract of the Caribbean sponge Agelas conifera collected 
from Belize [103]. Oxysceptrin (61) from the Okinawan ma-
rine sponge Agelas cf. nemoechinata showed active proper-
ties against actomyosin ATP-ase [104]. 
 Nakamuric  acid  (62) and sceptrin were identified from 
Australian sponges belonging to the genus Agelas [105]. 
Two dimeric bromopyrrole alkaloids, nakamuric acid (62) Cyclobutane-Containing Alkaloids  The Open Medicinal Chemistry Journal, 2008, Volume 2    35 
and its corresponding Me ester (63), were isolated from the 
Indopacific sponge Agelas nakamurai along with the known  
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metabolites sceptrin, debromosceptrin, and ageliferin. All 
compounds inhibited the growth of several Gram-positive 
and Gram-negative bacteria in the agar plate diffusion assay 
[106]. Six dimeric bromopyrrole alkaloids were isolated 
from a Florida Keys specimen of Agelas conifera. One of the 
constituents was identified as a new bromopyrrole metabo-
lite, bromosceptrin (64) [107]. 
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PREDICTED ACTIVITIES FOR MARINE ALKA-
LOIDS 
  Additional predicted activities for natural cyclobutane-
containing alkaloids are shown in Table 3. 
Table 3.  Predicted Biological Activities for Compounds Iso-
lated from Marine Sources 
 
No.  Drug-Likeness  Focal Activity Prediction 
48  0.704 Pa = 0.916, Pi = 0.005 Antiepileptic 
49  0.965 Pa = 0.669 Pi = 0.009 Prostaglandin E1 antagonist 
57  0.899 Pa = 0.682 Pi = 0.008 Prostaglandin E1 antagonist 
58  0.914 Pa = 0.719 Pi = 0.007 Prostaglandin E1 antagonist 
59  0.921 Pa = 0.719 Pi = 0.007 Prostaglandin E1 antagonist 
60  0.896 Pa = 0.616 Pi = 0.013 Prostaglandin E1 antagonist 
61  0.908 Pa = 0.625 Pi = 0.010 Prostaglandin E1 antagonist 
62  0.880 Pa = 0.672 Pi = 0.009 Prostaglandin E1 antagonist 
63  0.837 Pa = 0.631 Pi = 0.012 Prostaglandin E1 antagonist 
64  0.927 Pa = 0.682 Pi = 0.008 Prostaglandin E1 antagonist 
 
CONCLUDING REMARKS 
  Cyclobutane-containing alkaloids are rare group of natu-
ral products. They are mainly synthesized by different plant 
species, and also were detected in some marine species. A 
little information is known about biological activities of 
these metabolites. Nevertheless, reported activities for iso-
lated compounds revealed strong antibacterial, antimicrobial, 
antifeedant, antinociceptive, insecticidal and others activi-
ties. The widest spectra of pharmacological activities are 
exhibited by isolated alkaloids, and/or their N-oxides. Using 
the program PASS we showed that many reported activities 
for cyclobutane-containing alkaloids have been predicted, 
including some additional biological activities. 
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